JASPER THERAPEUTICS ($JSPR) posted quarterly earnings results for Q3 2026 on Monday, November 16th. The company reported earnings of -$13.97 per share, missing estimates of -$3.02 by $10.95. The company also reported revenue of $8,000,000, beating estimates of $3,060,000 by $4,940,000.
You can see Quiver Quantitative's $JSPR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
JASPER THERAPEUTICS Hedge Fund Activity
We have seen 23 institutional investors add shares of JASPER THERAPEUTICS stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AFFINITY ASSET ADVISORS, LLC added 1,850,000 shares (+inf%) to their portfolio in Q3 2026, for an estimated $32,189,999
- MILLENNIUM MANAGEMENT LLC removed 1,130,598 shares (-69.9%) from their portfolio in Q2 2026, for an estimated $475,981
- CARLYLE GROUP INC. removed 1,030,649 shares (-96.7%) from their portfolio in Q3 2026, for an estimated $17,933,292
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 385,522 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $162,304
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 322,273 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $135,676
- BANK OF AMERICA CORP /DE/ removed 279,067 shares (-95.2%) from their portfolio in Q2 2026, for an estimated $117,487
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 276,312 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $116,327
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
JASPER THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $JSPR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 10/14/2026
- Piper Sandler issued a "Overweight" rating on 08/12/2026
To track analyst ratings and price targets for JASPER THERAPEUTICS, check out Quiver Quantitative's $JSPR forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.